Loading...
  • depot
  • Limitations of use: The effects of octreotide (injection solution and LAR depot suspension) on tumor size, rate of growth, and development of metastases in patients with carcinoid syndrome and VIPomas have not been determined. (drugs.com)
  • injection depot technology. (lu.se)
  • drugs
  • A sustained release formulation by using dimeticone as the dispersion medium, which includes active ingredient (e.g., drugs against parasites, insecticides, NSAIDs, antibiotics, sex hormone like agents or oily soluble vitamins) and dimeticone as the medium. (patentgenius.com)
  • CN03138019.0, CN03156876.9, CN03148883.8 and CN03153569.0, and also includes dimethicone-based preparation of long-lasting action injection formulation used for drugssuch as anticoccidial drugs, sex hormone agents, imidacloprid, etc. (patentgenius.com)
  • As with other drugs administered by subcutaneous injection, the injection site should vary periodically. (nih.gov)
  • patients
  • RELISTOR tablets and injection are contraindicated in patients with known or suspected mechanical gastrointestinal obstruction and patients at increased risk of recurrent obstruction, due to the potential for gastrointestinal perforation. (relistor.com)
  • Injection solution: Management of symptoms (diarrhea and flushing) in patients with metastatic carcinoid tumors. (drugs.com)
  • APPLICATIONS
  • The course and the lecturers had a great wealth of the past, present, and future and did a good job of presenting the analytical tools and applications of formulation related topics. (mit.edu)
  • least
  • I am confident that the implant, if approved by FDA, will be at least as effective as a sublingual formulation and have the added benefits of reducing problems related to compliance, misuse and abuse. (appletreepartners.com)